AP-472
Asset
Adjunctive therapy to levodopa for motor fluctuations in Parkinson's disease.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Parkinson's disease
Phase 2, Recruiting, NCT07432958, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.